Literature DB >> 12678693

Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria.

John R Cashman1, Kathryn Camp, Steven S Fakharzadeh, Paul V Fennessey, Ronald N Hines, Orval A Mamer, Steven C Mitchell, George Preti Nguyen, Daniel Schlenk, Robert L Smith, Susan S Tjoa, David E Williams, Steven Yannicelli.   

Abstract

Trimethylaminuria is a rare metabolic disorder that is associated with abnormal amounts of the dietary-derived trimethylamine. Excess unmetabolized trimethylamine in the urine, sweat and other body secretions confers a strong, foul body odor that can affect the individual's ability to work or engage in social activities. This review summarizes the biochemical aspects of the condition and the classification of the disorder into: 1) primary genetic form, 2) acquired form, 3) childhood forms, 4) transient form associated with menstruation, 5) precursor overload and 6) disease states. The genetic variability of the flavin-containing monooxygenase (form 3) that is responsible for detoxication and deodoration of trimethylamine is discussed and put in context with other variant forms of the flavin-containing monooxygenase (forms 1-5). The temporal-selective expression of flavin-containing monooxygenase forms 1 and 3 is discussed in terms of an explanation for childhood trimethylaminuria. Information as to whether variants of the flavin-containing monooxygenase form 3 contributes to hypertension and/or other diseases are presented. Discussion is provided outlining recent bioanalytical approaches to quantify urinary trimethylamine and trimethylamine N-oxide and plasma choline as well as data on self-reporting individuals tested for trimethylaminuria. Finally, trimethylaminuria treatment strategies and nutritional support are described including dietary sources of trimethylamine, vitamin supplementation and drug treatment and issues related to trimethylaminuria in pregnancy and lactation are discussed. The remarkable progress in the biochemical, genetic, clinical basis for understanding the trimethylaminuria condition is summarized and points to needs in the treatment of individuals suffering from trimethylaminuria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12678693     DOI: 10.2174/1389200033489505

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  22 in total

1.  Clinical utility gene card for: trimethylaminuria.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2011-11-30       Impact factor: 4.246

2.  Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.

Authors:  Zeneng Wang; Adam B Roberts; Jennifer A Buffa; Bruce S Levison; Weifei Zhu; Elin Org; Xiaodong Gu; Ying Huang; Maryam Zamanian-Daryoush; Miranda K Culley; Anthony J DiDonato; Xiaoming Fu; Jennie E Hazen; Daniel Krajcik; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

3.  Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.

Authors:  Makiko Shimizu; Charles K Allerston; Elizabeth A Shephard; Hiroshi Yamazaki; Ian R Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

4.  Combined linkage and association analysis identifies rare and low frequency variants for blood pressure at 1q31.

Authors:  Heming Wang; Priyanka Nandakumar; Fasil Tekola-Ayele; Bamidele O Tayo; Erin B Ware; C Charles Gu; Yingchang Lu; Jie Yao; Wei Zhao; Jennifer A Smith; Jacklyn N Hellwege; Xiuqing Guo; Todd L Edwards; Ruth J F Loos; Donna K Arnett; Myriam Fornage; Charles Rotimi; Sharon L R Kardia; Richard S Cooper; D C Rao; Georg Ehret; Aravinda Chakravarti; Xiaofeng Zhu
Journal:  Eur J Hum Genet       Date:  2018-09-27       Impact factor: 4.246

Review 5.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

Review 6.  Flavin Containing Monooxygenases and Metabolism of Xenobiotics.

Authors:  Rahman Başaran; Benay Can Eke
Journal:  Turk J Pharm Sci       Date:  2017-04-15

Review 7.  Role of gut microbiota in atherosclerosis.

Authors:  Annika Lindskog Jonsson; Fredrik Bäckhed
Journal:  Nat Rev Cardiol       Date:  2016-12-01       Impact factor: 32.419

8.  Transient massive trimethylaminuria associated with food protein-induced enterocolitis syndrome.

Authors:  Natalie B Miller; Avraham Beigelman; Elizabeth Utterson; Marwan Shinawi
Journal:  JIMD Rep       Date:  2013-07-03

9.  A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota.

Authors:  Moustafa T Gabr; David Machalz; Szymon Pach; Gerhard Wolber
Journal:  RSC Med Chem       Date:  2020-08-28

10.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.